Published peer-reviewed data demonstrate bamlanivimab's high potency against sars-cov-2 and support its use as a foundational antibody therapy to treat and prevent covid-19

Vancouver, british columbia--(business wire)---- $abcl #covid19--published data show high potency of bamlanivimab against sars-cov-2 and support its clinical effectiveness to treat and prevent covid-19.
ABCL Ratings Summary
ABCL Quant Ranking